Invesco Markets Plc (SMLD) News

Indaptus Therapeutics to Present Positive Data on Lead Product Candidate, Decoy20, at STING & TLR-Targeted Therapies Summit

- Chief Scientific Officer Dr. Newman to present initial clinical data that further validates Company’s...

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Indaptus Therapeutics to Present New Positive Data on Decoy20 at Next-Gen Immuno-Oncology Conference

NEW YORK, June 04, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc, (Nasdaq: INDP), a clinical stage...

Indaptus Therapeutics Announces New Positive Data from Ongoing Phase 1 Trial of Decoy20

Latest data from first and second cohorts support Company’s 'pulse-prime' approach, demonstrating rapid...

Indaptus Therapeutics to Present at the Jefferies Global Healthcare Conference

NEW YORK, May 30, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical stage...

Indaptus Therapeutics to Present New Cohort Data Confirming Original “Pulse-Prime” Hypothesis Via Phase 1 Clinical Trial of Decoy20 at the American Society of Clinical Oncology Annual Meeting

NEW YORK, May 29, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc, (Nasdaq: INDP), a clinical stage...

Form 8-K - Current report

Indaptus Therapeutics Announces Completion of First Patient to Receive Multiple Doses of Decoy20, the Company’s Broad-Based, “Pulse-Prime” Immuno-Oncology Therapy for Advanced Solid Tumors

First-in-human trial confirms “Pulse-Prime” hypothesis targeting stimulation of innate and adaptive immune...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Indaptus Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

NEW YORK, May 08, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the...

Indaptus Therapeutics Presents Positive Mechanism of Action Data at the American Association for Cancer Research Annual Meeting

NEW YORK, April 11, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc, (Nasdaq: INDP), a clinical stage...

Indaptus Therapeutics to Present at the MedInvest Biotech and Pharma Investor Conference

NEW YORK, March 28, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical stage...

Indaptus Therapeutics Previews Positive Mechanism of Action Data to be Presented at the American Association for Cancer Research Annual Meeting

Data demonstrates that Company’s Decoy platform successfully induces or activates multiple immune cell types...